NCT03833531: PROSPER-C

Effectiveness of PTSD-treatment Compared to Integrated PTSD-PD-treatment in Adult Patients With Comorbid PTSD and CPD

Completed NA Last updated 7 June 2023

What this trial tests

NA trial testing ImRS in Posttraumatic Stress Disorder (PTSD) in 131 participants. Completed in 5 May 2023.

Timeline

1 June 2018

Primary endpoint
9 January 2023

5 May 2023

Quick facts

Lead sponsor	Arkin
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	131
Start date	1 June 2018
Primary completion	9 January 2023
Estimated completion	5 May 2023
Sites	1 location across Netherlands

Drugs / interventions tested

• ImRS
• SFT

Conditions studied

• Posttraumatic Stress Disorder (PTSD) — all drugs for Posttraumatic Stress Disorder (PTSD) →
• Avoidant Personality Disorder — all drugs for Avoidant Personality Disorder →
• Dependent Personality Disorder — all drugs for Dependent Personality Disorder →
• Obsessive Compulsive Personality Disorder — all drugs for Obsessive Compulsive Personality Disorder →

Sponsor

Arkin — full company profile →

Who can join

Adults 18 to 65, any sex, with Posttraumatic Stress Disorder (PTSD) or Avoidant Personality Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of PROSPER-C is to study effectiveness of ImRs compared to integrated SFT-ImRs in treatment-seeking, adult patients with comorbid PTSD and Cluster C Personality Disorder (CPD).

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. A randomized controlled trial comparing the clinical efficacy and cost-effectiveness of eye movement desensitization and reprocessing (EMDR) and integrated EMDR-Dialectical Behavioural Therapy (DBT) in the treatment of patients with post-traumatic stress disorder and comorbid (Su
   Snoek A, Beekman ATF, Dekker J, Aarts I, et al · · 2020 · cited 24× · PMID 32762677 · DOI 10.1186/s12888-020-02713-x
2. Trauma-focused and personality disorder treatment for posttraumatic stress disorder and comorbid cluster C personality disorder: a randomized clinical trial.
   van den End A, Beekman ATF, Dekker J, Aarts I, et al · · 2024 · cited 6× · PMID 39087734 · DOI 10.1080/20008066.2024.2382652
3. Clinical Efficacy and Cost-Effectiveness of Imagery Rescripting Only Compared to Imagery Rescripting and Schema Therapy in Adult Patients With PTSD and Comorbid Cluster C Personality Disorder: Study Design of a Randomized Controlled Trial.
   van den End A, Dekker J, Beekman ATF, Aarts I, et al · · 2021 · cited 6× · PMID 33868050 · DOI 10.3389/fpsyt.2021.633614
4. Treatment outcome is associated with pre-treatment connectome measures across psychiatric disorders - evidence for connectomic reserve?
   Vriend C, Fitzsimmons SMDD, Aarts I, Broekhuizen A, et al · · 2025 · cited 1× · PMID 40858071 · DOI 10.1016/j.nicl.2025.103870
5. Neural correlates of treatment effect and prediction of treatment outcome in patients with PTSD and comorbid personality disorder: study design.
   Aarts I, Vriend C, Snoek A, van den End A, et al · · 2021 · cited 1× · PMID 33947471 · DOI 10.1186/s40479-021-00156-8
6. Treatment outcome is associated with pre-treatment connectome measures across psychiatric disorders - evidence for connectomic reserve?
   Vriend C, Fitzsimmons SM, Aarts I, Broekhuizen A, et al · · 2025 · DOI 10.1101/2025.02.23.25322741